We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCM
176
DELISTED
R1 RCM Inc. Common Stock
RCM
| $31.9M | 0.15% |
2,457,375
-331,387
| -12% | -$3.78M |
|
177
Baker Hughes
BKR
$56.8B
| $31.7M | 0.14% |
1,234,956
+14,774
| +1% | +$336K |
|
|
VRNT
178
DELISTED
Verint Systems
VRNT
| $31.4M | 0.14% |
1,113,349
-149,168
| -12% | -$3.63M |
|
|
CALY
179
Callaway Golf Company
CALY
$3.26B
| $31.2M | 0.14% |
1,474,054
-195,165
| -12% | -$4M |
|
180
NeoGenomics
NEO
$1.81B
| $31.1M | 0.14% |
1,062,266
-141,881
| -12% | -$3.38M |
|
181
Edwards Lifesciences
EW
$47.6B
| $30.9M | 0.14% |
397,665
+14,331
| +4% | +$1.12M |
|
182
DaVita
DVA
$15.1B
| $30.8M | 0.14% |
409,961
+194,857
| +91% | +$12.9M |
|
|
HPP
183
Hudson Pacific Properties
HPP
$834M
| $30.6M | 0.14% |
116,011
-63,625
| -35% | -$15.7M |
|
184
Outfront Media
OUT
$5.64B
| $30.5M | 0.14% |
1,155,969
-156,928
| -12% | -$4.04M |
|
185
Hancock Whitney
HWC
$6.13B
| $30.5M | 0.14% |
695,246
+684,506
| +6,373% | +$27.8M |
|
186
Ulta Beauty
ULTA
$20.4B
| $30.3M | 0.14% |
119,818
+16,358
| +16% | +$4M |
|
187
Prologis
PLD
$138B
| $30.2M | 0.14% |
338,754
-18,464
| -5% | -$1.64M |
|
|
UMPQ
188
DELISTED
Umpqua Holdings Corp
UMPQ
| $30M | 0.14% |
1,696,851
-191,333
| -10% | -$3.17M |
|
189
Ziff Davis
ZD
$1.9B
| $30M | 0.14% |
368,524
-49,805
| -12% | -$4.12M |
|
190
Snap-on
SNA
$20.9B
| $29.8M | 0.14% |
175,749
-131,242
| -43% | -$21.4M |
|
191
Dow Inc
DOW
$21.6B
| $29.7M | 0.14% |
543,405
-5,740
| -1% | -$297K |
|
|
HI
192
DELISTED
Hillenbrand
HI
| $29.7M | 0.14% |
891,462
-110,396
| -11% | -$3.49M |
|
193
Vanguard Total Stock Market ETF
VTI
$654B
| $29.5M | 0.13% |
180,226
+29,098
| +19% | +$4.56M |
|
|
DOOR
194
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $29.2M | 0.13% |
403,751
-53,052
| -12% | -$3.49M |
|
|
TVTY
195
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $29M | 0.13% |
1,427,816
-190,210
| -12% | -$3.56M |
|
|
EFOR
196
Everforth Inc
EFOR
$845M
| $28.8M | 0.13% |
406,472
+126,109
| +45% | +$8.23M |
|
197
Evercore
EVR
$13.1B
| $28.8M | 0.13% |
385,563
-46,402
| -11% | -$3.54M |
|
198
PPG Industries
PPG
$25.9B
| $28.8M | 0.13% |
215,574
+162,585
| +307% | +$20.6M |
|
199
Timken Company
TKR
$9.82B
| $28.8M | 0.13% |
510,794
+172,962
| +51% | +$8.74M |
|
200
Norwegian Cruise Line
NCLH
$8.89B
| $28.7M | 0.13% |
491,033
+446,915
| +1,013% | +$23.6M |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.